European Journal of Preventive Medicine

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast)

The objective is to describe the epidemiological, clinical and therapeutic aspects of retinal damage in sickle cell disease. This was a cross-sectional, descriptive and analytical study, conducted from November 2022 to February 2023, i. e. for a period of 4 months in a private ophthalmology centre in Abidjan and at the University Hospital of Cocody (Côte d'Ivoire). It focused on sickle cell patients seen in consultation. A total of 50 patients, i. e. 100 eyes were included, corresponding to the sample. The data were entered and analysed using SPSS software. The mean age of the patients was 30 years ±10.495. Sickle cell disease SC was the most frequent form (52%). Half of the eyes (50%) had retinal damage with 34% of proliferative retinopathy (34 eyes). The most common Goldberg angiographic stage was stage III (73.53%). Laser photocoagulation was performed in stage III eyes. Retinal damage in sickle cell disease is common and is most often seen in SC patients. Stage III neovascularisation is the barrier that must not be crossed, as the consequences are dramatic with irreversible blindness. Laser photocoagulation is necessary to prevent the formation or to promote the regression of neovessels. Screening should be annual and especially with fluorescein retinal angiography.

Retinal Neovascularisation, Sickle Cell, Epidemiology

APA Style

Koman Chiatse Ellalie, Kouassi Colette Rebours, Agbohoun Reine Prisca, N’da Hermine Cynthia, Konan Manmi Sienou Marguerite Pascaline, et al. (2023). Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast). European Journal of Preventive Medicine, 11(4), 48-52.

ACS Style

Koman Chiatse Ellalie; Kouassi Colette Rebours; Agbohoun Reine Prisca; N’da Hermine Cynthia; Konan Manmi Sienou Marguerite Pascaline, et al. Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast). Eur. J. Prev. Med. 2023, 11(4), 48-52. doi: 10.11648/j.ejpm.20231104.12

AMA Style

Koman Chiatse Ellalie, Kouassi Colette Rebours, Agbohoun Reine Prisca, N’da Hermine Cynthia, Konan Manmi Sienou Marguerite Pascaline, et al. Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast). Eur J Prev Med. 2023;11(4):48-52. doi: 10.11648/j.ejpm.20231104.12

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Beutler E, Lichtman M, Coller B, Kipps T. Hemoglobinopathies associated with unstable hemoglobin. Williams’ Hematol N Y McGraw Hill. 1995; 650-4.
2. Kakou-Danho B, Atiméré YN, Koné D, Akroman M, Boka A, Diakité L. Prévalence des hémoglobinopathies au laboratoire central du CHU de Treichville à Abidjan. Rev int sc méd Abj. 2020; 22, 3: 210-215.
3. Bonanomi MTBC, Lavezzo MM. Sickle cell retinopathy: diagnosis and treatment. Arq Bras Oftalmol. oct 2013; 76: 320-7.
4. Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010; 85 (1): 6-13.
5. Dembélé AK, Toure BA, Sarro YS, Guindo A, Fané B, Offredo L, et al. Prévalence et facteurs de risque de la rétinopathie drépanocytaire dans un centre de suivi drépanocytaire d’Afrique subsaharienne. Rev Médecine Interne. 1 sept 2017; 38 (9): 572-7.
6. Leveziel N, Lalloum F, Bastuji-Garin S, Binaghi M, Bachir D, Galacteros F, et al. Rétinopathie drépanocytaire: analyse rétrospective portant sur 730 patients suivis dans un centre de référence. J Fr Ophtalmol. 1 mai 2012; 35 (5): 343-7.
7. Fanny A, Coulibaly F, Gbe K, Meite M, Adjorlolo C, Konan-Toure ML, et al. Les bêtathalasso-drépanocytoses pourvoyeuses de rétinopathies ischémiques graves: À propos de 18 patients étudiés à Abidjan. J Fr Ophtalmol. 2005; 28 (4): 391-5.
8. Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol. 1971; 71 (3): 649-65.
9. Odoulami-Yehouessi L, Hounnou-Tchabi S, Anani L, Sounouvou I, Sagbohan V, Dehoumon J, et al. La rétinopathie drépanocytaire au CNHU-HKM de Cotonou: à propos de 53 cas. Rev CAMES. 2009; 08 (Serie A): 28-31.
10. Fany A, Boni S, Adjorlolo C, Konan MT, Gbe K, Coulibaly F, et al. La rétinopathie chez le porteur du trait drépanocytaire AS: mythe ou réalité? J Fr Ophtalmol. 2004; 27 (9): 1025-30.
11. Conaré I, Sidibé M, Napo A, Guirou N, Guindo A, Bakayoko S, et al. Prise En Charge De La Retinopathie Drepanocytaire: A Propos De 119 Cas Au Chu-Iota. Rev SOAO-N. 2018; 38-42.
12. Akinsola F, Kehinde M. Ocular findings in sickle cell disease patients in Lagos. Niger Postgrad Med J. 2004; 11 (3): 203-6.
13. Binaghi M, Levy C., 1993. Œil et hémoglobinopathies. Encyclopédie Médico-Chirurgicale. Ophtalmologie, 21- 452-G-20.7p.
14. Balo KP, Segbena K, Mensah A, Mihluedo H, Bechetoille A. Hemoglobinopathies and retinopathies in Lomé UHC. J Fr Ophtalmol. 1996; 19 (8-9): 497-504.
15. Diallo J, Sanfo O, Blot I, Meda N, Sawadogo P, Ouedraogo A, et al. Étude épidémiologique et facteurs pronostiques de la rétinopathie drépanocytaire à Ouagadougou (Burkina Faso). J Fr Ophtalmol. 2009; 32 (7): 496-500.